Physician profile
John W Howard
NPI 1205090065
$7,431.54
in general payments reported to CMS, 2019-2025
41 companies · $1,270 in 2025
The $1,270 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,436 · 2020: $452 · 2021: $670 · 2022: $1,355 · 2023: $1,121 · 2024: $1,127 · 2025: $1,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,519.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,105.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $753.16 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $741.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $499.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $379.05 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Novartis Pharmaceuticals Corporation | $372.32 | 2019-2023 | |
| Amgen INC. | $357.02 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $345.52 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $340.87 | 2019-2024 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $243.70 | 2022-2025 | |
| Astellas Pharma US INC | $242.31 | 2019-2025 | Veozah |
| Abbott Laboratories | $198.64 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.12 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Dexcom, INC. | $187.07 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $182.54 | 2019-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.